Cash Flow Statement

Amortization Amortization Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Cash Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation

Daily Values

Growth Metrics

Others

EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Outstanding Shares Outstanding

Ratios

Addex Therapeutics (ADXN) Shares Issued (2021 - 2023)

Addex Therapeutics' Shares Issued history spans 2 years, with the latest figure at $10.4 billion for Q3 2023.

On a quarterly basis, Shares Issued changed N/A to $10.4 billion in Q3 2023 year-over-year; TTM through Sep 2023 was $10.4 billion, a N/A change, with the full-year FY2021 number at $11.0 million, changed N/A from a year prior.
Shares Issued came in at $10.4 billion for Q3 2023, up from $11.2 million in the prior quarter.
The five-year high for Shares Issued was $10.4 billion in Q3 2023, with the low at $11.2 million in Q1 2021.